Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV

Background We sought to compare self‐reported alcohol consumption using Timeline Followback (TLFB) to biomarker‐based evidence of significant alcohol use (phosphatidylethanol [PEth] > 20 ng/ml). Using data from patients with HIV (PWH) entering a clinical trial, we asked whether TLFB could predict...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alcoholism, clinical and experimental research clinical and experimental research, 2020-10, Vol.44 (10), p.2053-2063
Hauptverfasser: Eyawo, Oghenowede, Deng, Yanhong, Dziura, James, Justice, Amy C., McGinnis, Kathleen, Tate, Janet P., Rodriguez‐Barradas, Maria C., Hansen, Nathan B., Maisto, Stephen A., Marconi, Vincent C., O’Connor, Patrick G., Bryant, Kendall, Fiellin, David A., Edelman, E. Jennifer
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2063
container_issue 10
container_start_page 2053
container_title Alcoholism, clinical and experimental research
container_volume 44
creator Eyawo, Oghenowede
Deng, Yanhong
Dziura, James
Justice, Amy C.
McGinnis, Kathleen
Tate, Janet P.
Rodriguez‐Barradas, Maria C.
Hansen, Nathan B.
Maisto, Stephen A.
Marconi, Vincent C.
O’Connor, Patrick G.
Bryant, Kendall
Fiellin, David A.
Edelman, E. Jennifer
description Background We sought to compare self‐reported alcohol consumption using Timeline Followback (TLFB) to biomarker‐based evidence of significant alcohol use (phosphatidylethanol [PEth] > 20 ng/ml). Using data from patients with HIV (PWH) entering a clinical trial, we asked whether TLFB could predict PEth > 20 ng/ml and assessed the magnitude of association between TLFB and PEth level. Methods We defined unhealthy alcohol use as any alcohol use in the presence of liver disease, at‐risk drinking, or alcohol use disorder. Self‐reported alcohol use obtained from TLFB interview was assessed as mean number of drinks/day and number of heavy drinking days over the past 21 days. Dried blood spot samples for PEth were collected at the interview. We used logistic regression to predict PEth > 20 ng/ml and Spearman correlation to quantify the association with PEth, both as a function of TLFB. Results Among 282 individuals (99% men) in the analytic sample, approximately two‐thirds (69%) of individuals had PEth > 20 ng/ml. The proportion with PEth > 20 ng/ml increased with increasing levels of self‐reported alcohol use; of the 190 patients with either at‐risk drinking or alcohol use disorder based on self‐report, 82% had PEth > 20 ng/ml. Discrimination was better with number of drinks per day than heavy drinking days (AUC: 0.80 [95% CI: 0.74 to 0.85] vs. 0.74 [95% CI: 0.68 to 0.80]). The number of drinks per day and PEth were significantly and positively correlated across all levels of alcohol use (Spearman’s R ranged from 0.29 to 0.56, all p values 20 ng/ml), and whether TLFB could discriminate individuals with evidence of significant alcohol by PEth. We found mean numbers of drinks/day discriminated individuals with PEth evidence of significant alcohol use. PEth complements self‐report to improve alcohol measurement in clinical settings and trials.
doi_str_mv 10.1111/acer.14435
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8856627</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2478774435</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4485-72364362aa777d70029bb9c98e3f20f0b7d285dd275fa621bd301f1cad888eaa3</originalsourceid><addsrcrecordid>eNp9kc1qGzEYRUVISNy0mz5AGcgmDUyqf8mbgjHODwRq0jpdCs1IE02QR640bvEuj9Bn7JNEZpyQdlFttLhHh0_fBeA9gucon0-6tvEcUUrYHhghRmAJsRD7YAQRZSWHUB6BNyk9QAip5PwQHBFCOcSYjYC70741um-7--Kr9c2fx9-3dhVib02x6JzVvnebYuLr4IIvFskW39veFXMX0srlZ2bjbe90l8PT-ax3H4vJMmTXPGe269OAX13fvQUHjfbJvtvdx2BxMfs2vSpvvlxeTyc3ZU2pZKXAhFPCsdZCCCMgxOOqGtdjaUmDYQMrYbBkxmDBGs0xqgyBqEG1NlJKqzU5Bp8H72pdLa2p8xBRe7WK7VLHjQq6VX8nXevUffippGScY5EFpztBDD_WNvVq2abaeq87G9ZJYSqkENttZ_TkH_QhrGOXv5cphlDe9phm6myg6hhSirZ5GQZBtS1QbQtUaKf88Hr8F_S5sQygAfjVerv5j0pNprPbQfoEh6CnBw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2451148694</pqid></control><display><type>article</type><title>Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Eyawo, Oghenowede ; Deng, Yanhong ; Dziura, James ; Justice, Amy C. ; McGinnis, Kathleen ; Tate, Janet P. ; Rodriguez‐Barradas, Maria C. ; Hansen, Nathan B. ; Maisto, Stephen A. ; Marconi, Vincent C. ; O’Connor, Patrick G. ; Bryant, Kendall ; Fiellin, David A. ; Edelman, E. Jennifer</creator><creatorcontrib>Eyawo, Oghenowede ; Deng, Yanhong ; Dziura, James ; Justice, Amy C. ; McGinnis, Kathleen ; Tate, Janet P. ; Rodriguez‐Barradas, Maria C. ; Hansen, Nathan B. ; Maisto, Stephen A. ; Marconi, Vincent C. ; O’Connor, Patrick G. ; Bryant, Kendall ; Fiellin, David A. ; Edelman, E. Jennifer</creatorcontrib><description>Background We sought to compare self‐reported alcohol consumption using Timeline Followback (TLFB) to biomarker‐based evidence of significant alcohol use (phosphatidylethanol [PEth] &gt; 20 ng/ml). Using data from patients with HIV (PWH) entering a clinical trial, we asked whether TLFB could predict PEth &gt; 20 ng/ml and assessed the magnitude of association between TLFB and PEth level. Methods We defined unhealthy alcohol use as any alcohol use in the presence of liver disease, at‐risk drinking, or alcohol use disorder. Self‐reported alcohol use obtained from TLFB interview was assessed as mean number of drinks/day and number of heavy drinking days over the past 21 days. Dried blood spot samples for PEth were collected at the interview. We used logistic regression to predict PEth &gt; 20 ng/ml and Spearman correlation to quantify the association with PEth, both as a function of TLFB. Results Among 282 individuals (99% men) in the analytic sample, approximately two‐thirds (69%) of individuals had PEth &gt; 20 ng/ml. The proportion with PEth &gt; 20 ng/ml increased with increasing levels of self‐reported alcohol use; of the 190 patients with either at‐risk drinking or alcohol use disorder based on self‐report, 82% had PEth &gt; 20 ng/ml. Discrimination was better with number of drinks per day than heavy drinking days (AUC: 0.80 [95% CI: 0.74 to 0.85] vs. 0.74 [95% CI: 0.68 to 0.80]). The number of drinks per day and PEth were significantly and positively correlated across all levels of alcohol use (Spearman’s R ranged from 0.29 to 0.56, all p values &lt; 0.01). Conclusions In this sample of PWH entering a clinical trial, mean numbers of drinks per day discriminated individuals with evidence of significant alcohol use by PEth. PEth complements self‐report to improve identification of self‐reported unhealthy alcohol use among PWH. Among patients with HIV entering a clinical trial, we assessed the magnitude of association between self‐reported alcohol consumption (using Timeline Followback (TLFB)) and a biomarker‐based evidence of significant alcohol use (using phosphatidylethanol [PEth] with a cut‐off &gt;20 ng/ml), and whether TLFB could discriminate individuals with evidence of significant alcohol by PEth. We found mean numbers of drinks/day discriminated individuals with PEth evidence of significant alcohol use. PEth complements self‐report to improve alcohol measurement in clinical settings and trials.</description><identifier>ISSN: 0145-6008</identifier><identifier>EISSN: 1530-0277</identifier><identifier>DOI: 10.1111/acer.14435</identifier><identifier>PMID: 33460225</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Alcohol Drinking ; Alcohol Use ; Alcoholic beverages ; Alcoholism - blood ; Alcoholism - diagnosis ; Alcoholism - psychology ; Biomarker ; Biomarkers ; Clinical trials ; Drinking behavior ; Female ; Glycerophospholipids - blood ; HIV ; HIV Infections - complications ; HIV Infections - psychology ; Human immunodeficiency virus ; Humans ; Liver diseases ; Male ; Middle Aged ; PEth ; Phosphatidylethanol ; Predictive Value of Tests ; Self Report ; Sensitivity and Specificity ; Socioeconomic Factors ; Timeline Followback ; TLFB</subject><ispartof>Alcoholism, clinical and experimental research, 2020-10, Vol.44 (10), p.2053-2063</ispartof><rights>2020 by the Research Society on Alcoholism</rights><rights>2020 by the Research Society on Alcoholism.</rights><rights>2020 Research Society on Alcoholism</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4485-72364362aa777d70029bb9c98e3f20f0b7d285dd275fa621bd301f1cad888eaa3</citedby><cites>FETCH-LOGICAL-c4485-72364362aa777d70029bb9c98e3f20f0b7d285dd275fa621bd301f1cad888eaa3</cites><orcidid>0000-0003-0139-5502 ; 0000-0002-9375-0489 ; 0000-0001-6263-1076 ; 0000-0002-4006-010X ; 0000-0001-5470-102X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Facer.14435$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Facer.14435$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33460225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eyawo, Oghenowede</creatorcontrib><creatorcontrib>Deng, Yanhong</creatorcontrib><creatorcontrib>Dziura, James</creatorcontrib><creatorcontrib>Justice, Amy C.</creatorcontrib><creatorcontrib>McGinnis, Kathleen</creatorcontrib><creatorcontrib>Tate, Janet P.</creatorcontrib><creatorcontrib>Rodriguez‐Barradas, Maria C.</creatorcontrib><creatorcontrib>Hansen, Nathan B.</creatorcontrib><creatorcontrib>Maisto, Stephen A.</creatorcontrib><creatorcontrib>Marconi, Vincent C.</creatorcontrib><creatorcontrib>O’Connor, Patrick G.</creatorcontrib><creatorcontrib>Bryant, Kendall</creatorcontrib><creatorcontrib>Fiellin, David A.</creatorcontrib><creatorcontrib>Edelman, E. Jennifer</creatorcontrib><title>Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV</title><title>Alcoholism, clinical and experimental research</title><addtitle>Alcohol Clin Exp Res</addtitle><description>Background We sought to compare self‐reported alcohol consumption using Timeline Followback (TLFB) to biomarker‐based evidence of significant alcohol use (phosphatidylethanol [PEth] &gt; 20 ng/ml). Using data from patients with HIV (PWH) entering a clinical trial, we asked whether TLFB could predict PEth &gt; 20 ng/ml and assessed the magnitude of association between TLFB and PEth level. Methods We defined unhealthy alcohol use as any alcohol use in the presence of liver disease, at‐risk drinking, or alcohol use disorder. Self‐reported alcohol use obtained from TLFB interview was assessed as mean number of drinks/day and number of heavy drinking days over the past 21 days. Dried blood spot samples for PEth were collected at the interview. We used logistic regression to predict PEth &gt; 20 ng/ml and Spearman correlation to quantify the association with PEth, both as a function of TLFB. Results Among 282 individuals (99% men) in the analytic sample, approximately two‐thirds (69%) of individuals had PEth &gt; 20 ng/ml. The proportion with PEth &gt; 20 ng/ml increased with increasing levels of self‐reported alcohol use; of the 190 patients with either at‐risk drinking or alcohol use disorder based on self‐report, 82% had PEth &gt; 20 ng/ml. Discrimination was better with number of drinks per day than heavy drinking days (AUC: 0.80 [95% CI: 0.74 to 0.85] vs. 0.74 [95% CI: 0.68 to 0.80]). The number of drinks per day and PEth were significantly and positively correlated across all levels of alcohol use (Spearman’s R ranged from 0.29 to 0.56, all p values &lt; 0.01). Conclusions In this sample of PWH entering a clinical trial, mean numbers of drinks per day discriminated individuals with evidence of significant alcohol use by PEth. PEth complements self‐report to improve identification of self‐reported unhealthy alcohol use among PWH. Among patients with HIV entering a clinical trial, we assessed the magnitude of association between self‐reported alcohol consumption (using Timeline Followback (TLFB)) and a biomarker‐based evidence of significant alcohol use (using phosphatidylethanol [PEth] with a cut‐off &gt;20 ng/ml), and whether TLFB could discriminate individuals with evidence of significant alcohol by PEth. We found mean numbers of drinks/day discriminated individuals with PEth evidence of significant alcohol use. PEth complements self‐report to improve alcohol measurement in clinical settings and trials.</description><subject>Adult</subject><subject>Aged</subject><subject>Alcohol Drinking</subject><subject>Alcohol Use</subject><subject>Alcoholic beverages</subject><subject>Alcoholism - blood</subject><subject>Alcoholism - diagnosis</subject><subject>Alcoholism - psychology</subject><subject>Biomarker</subject><subject>Biomarkers</subject><subject>Clinical trials</subject><subject>Drinking behavior</subject><subject>Female</subject><subject>Glycerophospholipids - blood</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - psychology</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Middle Aged</subject><subject>PEth</subject><subject>Phosphatidylethanol</subject><subject>Predictive Value of Tests</subject><subject>Self Report</subject><subject>Sensitivity and Specificity</subject><subject>Socioeconomic Factors</subject><subject>Timeline Followback</subject><subject>TLFB</subject><issn>0145-6008</issn><issn>1530-0277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1qGzEYRUVISNy0mz5AGcgmDUyqf8mbgjHODwRq0jpdCs1IE02QR640bvEuj9Bn7JNEZpyQdlFttLhHh0_fBeA9gucon0-6tvEcUUrYHhghRmAJsRD7YAQRZSWHUB6BNyk9QAip5PwQHBFCOcSYjYC70741um-7--Kr9c2fx9-3dhVib02x6JzVvnebYuLr4IIvFskW39veFXMX0srlZ2bjbe90l8PT-ax3H4vJMmTXPGe269OAX13fvQUHjfbJvtvdx2BxMfs2vSpvvlxeTyc3ZU2pZKXAhFPCsdZCCCMgxOOqGtdjaUmDYQMrYbBkxmDBGs0xqgyBqEG1NlJKqzU5Bp8H72pdLa2p8xBRe7WK7VLHjQq6VX8nXevUffippGScY5EFpztBDD_WNvVq2abaeq87G9ZJYSqkENttZ_TkH_QhrGOXv5cphlDe9phm6myg6hhSirZ5GQZBtS1QbQtUaKf88Hr8F_S5sQygAfjVerv5j0pNprPbQfoEh6CnBw</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Eyawo, Oghenowede</creator><creator>Deng, Yanhong</creator><creator>Dziura, James</creator><creator>Justice, Amy C.</creator><creator>McGinnis, Kathleen</creator><creator>Tate, Janet P.</creator><creator>Rodriguez‐Barradas, Maria C.</creator><creator>Hansen, Nathan B.</creator><creator>Maisto, Stephen A.</creator><creator>Marconi, Vincent C.</creator><creator>O’Connor, Patrick G.</creator><creator>Bryant, Kendall</creator><creator>Fiellin, David A.</creator><creator>Edelman, E. Jennifer</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K7.</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0139-5502</orcidid><orcidid>https://orcid.org/0000-0002-9375-0489</orcidid><orcidid>https://orcid.org/0000-0001-6263-1076</orcidid><orcidid>https://orcid.org/0000-0002-4006-010X</orcidid><orcidid>https://orcid.org/0000-0001-5470-102X</orcidid></search><sort><creationdate>202010</creationdate><title>Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV</title><author>Eyawo, Oghenowede ; Deng, Yanhong ; Dziura, James ; Justice, Amy C. ; McGinnis, Kathleen ; Tate, Janet P. ; Rodriguez‐Barradas, Maria C. ; Hansen, Nathan B. ; Maisto, Stephen A. ; Marconi, Vincent C. ; O’Connor, Patrick G. ; Bryant, Kendall ; Fiellin, David A. ; Edelman, E. Jennifer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4485-72364362aa777d70029bb9c98e3f20f0b7d285dd275fa621bd301f1cad888eaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alcohol Drinking</topic><topic>Alcohol Use</topic><topic>Alcoholic beverages</topic><topic>Alcoholism - blood</topic><topic>Alcoholism - diagnosis</topic><topic>Alcoholism - psychology</topic><topic>Biomarker</topic><topic>Biomarkers</topic><topic>Clinical trials</topic><topic>Drinking behavior</topic><topic>Female</topic><topic>Glycerophospholipids - blood</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - psychology</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Middle Aged</topic><topic>PEth</topic><topic>Phosphatidylethanol</topic><topic>Predictive Value of Tests</topic><topic>Self Report</topic><topic>Sensitivity and Specificity</topic><topic>Socioeconomic Factors</topic><topic>Timeline Followback</topic><topic>TLFB</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eyawo, Oghenowede</creatorcontrib><creatorcontrib>Deng, Yanhong</creatorcontrib><creatorcontrib>Dziura, James</creatorcontrib><creatorcontrib>Justice, Amy C.</creatorcontrib><creatorcontrib>McGinnis, Kathleen</creatorcontrib><creatorcontrib>Tate, Janet P.</creatorcontrib><creatorcontrib>Rodriguez‐Barradas, Maria C.</creatorcontrib><creatorcontrib>Hansen, Nathan B.</creatorcontrib><creatorcontrib>Maisto, Stephen A.</creatorcontrib><creatorcontrib>Marconi, Vincent C.</creatorcontrib><creatorcontrib>O’Connor, Patrick G.</creatorcontrib><creatorcontrib>Bryant, Kendall</creatorcontrib><creatorcontrib>Fiellin, David A.</creatorcontrib><creatorcontrib>Edelman, E. Jennifer</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Criminal Justice (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Alcoholism, clinical and experimental research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eyawo, Oghenowede</au><au>Deng, Yanhong</au><au>Dziura, James</au><au>Justice, Amy C.</au><au>McGinnis, Kathleen</au><au>Tate, Janet P.</au><au>Rodriguez‐Barradas, Maria C.</au><au>Hansen, Nathan B.</au><au>Maisto, Stephen A.</au><au>Marconi, Vincent C.</au><au>O’Connor, Patrick G.</au><au>Bryant, Kendall</au><au>Fiellin, David A.</au><au>Edelman, E. Jennifer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV</atitle><jtitle>Alcoholism, clinical and experimental research</jtitle><addtitle>Alcohol Clin Exp Res</addtitle><date>2020-10</date><risdate>2020</risdate><volume>44</volume><issue>10</issue><spage>2053</spage><epage>2063</epage><pages>2053-2063</pages><issn>0145-6008</issn><eissn>1530-0277</eissn><abstract>Background We sought to compare self‐reported alcohol consumption using Timeline Followback (TLFB) to biomarker‐based evidence of significant alcohol use (phosphatidylethanol [PEth] &gt; 20 ng/ml). Using data from patients with HIV (PWH) entering a clinical trial, we asked whether TLFB could predict PEth &gt; 20 ng/ml and assessed the magnitude of association between TLFB and PEth level. Methods We defined unhealthy alcohol use as any alcohol use in the presence of liver disease, at‐risk drinking, or alcohol use disorder. Self‐reported alcohol use obtained from TLFB interview was assessed as mean number of drinks/day and number of heavy drinking days over the past 21 days. Dried blood spot samples for PEth were collected at the interview. We used logistic regression to predict PEth &gt; 20 ng/ml and Spearman correlation to quantify the association with PEth, both as a function of TLFB. Results Among 282 individuals (99% men) in the analytic sample, approximately two‐thirds (69%) of individuals had PEth &gt; 20 ng/ml. The proportion with PEth &gt; 20 ng/ml increased with increasing levels of self‐reported alcohol use; of the 190 patients with either at‐risk drinking or alcohol use disorder based on self‐report, 82% had PEth &gt; 20 ng/ml. Discrimination was better with number of drinks per day than heavy drinking days (AUC: 0.80 [95% CI: 0.74 to 0.85] vs. 0.74 [95% CI: 0.68 to 0.80]). The number of drinks per day and PEth were significantly and positively correlated across all levels of alcohol use (Spearman’s R ranged from 0.29 to 0.56, all p values &lt; 0.01). Conclusions In this sample of PWH entering a clinical trial, mean numbers of drinks per day discriminated individuals with evidence of significant alcohol use by PEth. PEth complements self‐report to improve identification of self‐reported unhealthy alcohol use among PWH. Among patients with HIV entering a clinical trial, we assessed the magnitude of association between self‐reported alcohol consumption (using Timeline Followback (TLFB)) and a biomarker‐based evidence of significant alcohol use (using phosphatidylethanol [PEth] with a cut‐off &gt;20 ng/ml), and whether TLFB could discriminate individuals with evidence of significant alcohol by PEth. We found mean numbers of drinks/day discriminated individuals with PEth evidence of significant alcohol use. PEth complements self‐report to improve alcohol measurement in clinical settings and trials.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33460225</pmid><doi>10.1111/acer.14435</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-0139-5502</orcidid><orcidid>https://orcid.org/0000-0002-9375-0489</orcidid><orcidid>https://orcid.org/0000-0001-6263-1076</orcidid><orcidid>https://orcid.org/0000-0002-4006-010X</orcidid><orcidid>https://orcid.org/0000-0001-5470-102X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0145-6008
ispartof Alcoholism, clinical and experimental research, 2020-10, Vol.44 (10), p.2053-2063
issn 0145-6008
1530-0277
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8856627
source MEDLINE; Wiley Online Library All Journals
subjects Adult
Aged
Alcohol Drinking
Alcohol Use
Alcoholic beverages
Alcoholism - blood
Alcoholism - diagnosis
Alcoholism - psychology
Biomarker
Biomarkers
Clinical trials
Drinking behavior
Female
Glycerophospholipids - blood
HIV
HIV Infections - complications
HIV Infections - psychology
Human immunodeficiency virus
Humans
Liver diseases
Male
Middle Aged
PEth
Phosphatidylethanol
Predictive Value of Tests
Self Report
Sensitivity and Specificity
Socioeconomic Factors
Timeline Followback
TLFB
title Validating Self‐Reported Unhealthy Alcohol Use With Phosphatidylethanol (PEth) Among Patients With HIV
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T20%3A36%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validating%20Self%E2%80%90Reported%20Unhealthy%20Alcohol%20Use%20With%20Phosphatidylethanol%20(PEth)%20Among%20Patients%20With%20HIV&rft.jtitle=Alcoholism,%20clinical%20and%20experimental%20research&rft.au=Eyawo,%20Oghenowede&rft.date=2020-10&rft.volume=44&rft.issue=10&rft.spage=2053&rft.epage=2063&rft.pages=2053-2063&rft.issn=0145-6008&rft.eissn=1530-0277&rft_id=info:doi/10.1111/acer.14435&rft_dat=%3Cproquest_pubme%3E2478774435%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2451148694&rft_id=info:pmid/33460225&rfr_iscdi=true